Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.79 |
| ▸ | PIK3CA | P42336 | 19/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.60 |
| ▸ | ATR | Q13535 | 4/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597659 | 0.93 | MTOR (0.80) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL14794908 | 0.92 | MTOR (0.78) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL14790916 | 0.91 | MTOR (0.75) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL3145907 | 0.91 | MTOR (0.64) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL7920905 | 0.91 | MTOR (0.64) | MTORPIK3CAPIK3CGATR | |
| Hydrochloric Acid SCHEMBL1359560 | 0.90 | MTOR (0.64) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL14776742 | 0.89 | MTOR (1.00) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL2597679 | 0.88 | MTOR (0.83) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL14790908 | 0.88 | MTOR (0.88) | MTORPIK3CAPIK3CGATRPIK3CD | |
| SCHEMBL14776663 | 0.88 | MTOR (0.91) | MTORPIK3CAPIK3CGATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | claimed |
| EP-2571884-A2 | MTOR SELECTIVE KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2013-03-27 | — | — | EP | claimed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | claimed |
| WO-2011146594-A2 | MTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC. (US) | 2011-11-24 | — | — | WO | claimed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2571884-A2 | MTOR SELECTIVE KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011146594-A2 | MTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | MTOR, ULK1, ULK2 | MTOR 1/4885PIK3CA 69/4885PIK3CG 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.